[국제]UK Enters Phase 1 ‘Immediate Immunity’ Antibody Treatment … Will It Become Another ‘Armor’?

[앵커]

Following the vaccine, the UK government has entered the clinical trial of an antibody treatment that has a rapid immunological effect.

In a situation where the number of confirmed cases and deaths is increasing rapidly, it appears to be aimed at preventing the worsening of symptoms in confirmed cases early and reducing the number of deaths until the vaccine is widely distributed.

This is reporter Kim Jeong-hoe.

[기자]

The UK faces the worst Corona 19 situation every day.

The spread of the mutant virus is out of control.

Four additional passes have been issued in four areas, including Sussex and Norfolk, which in fact banned 40% of the UK population.

[맷 행콕 / 영국 보건부 장관 : 이 변이 바이러스는 끔찍했던 올 한 해를 믿을 수 없을 정도로 어려운 결말로 끌어가고 있습니다.]

The vaccination started this month, but the time when group immunity is expected is next summer as most of the people have completed the vaccination.

Special measures are needed to fill the gaps in time and break the expansion trend immediately.

The British government has chosen an antibody treatment.

According to The Guardian, phase 1 clinical trials have already started and efficacy and safety are being monitored.

Subjects were initially confirmed and suspected patients within 8 days of Corona 19 exposure.

To see if it is asymptomatic or mild to prevent symptoms from getting worse.

It is a supervised observation task that has a preventive effect for 6 to 12 months.

Currently, the drug is being developed jointly by the pharmaceutical company AstraZeneca and the University Hospital of London.

It is not an antibody extracted from a cure, but a single antibody produced in the laboratory that binds only to a specific antigen. This is a two-time inoculation method.

In fact, the vaccine takes several weeks to be effective and is ineffective if the virus has already entered the body.

However, antibody treatments can neutralize the virus as soon as they are attacked, so we can expect another shielding function from vaccines.

Therefore, the first drug is expected to be used to block the spread of infection between hospitalized patients and residents of nursing facilities, homes with confirmed cases, and college students with many group activities.

Practical use is expected to start in March-April next year after review and approval by the UK pharmaceutical regulatory authorities.

This is YTN Kim Jeong-hoe.

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]